

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: April 24, 2002

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 09/935,767
Filing Date 08/24/2001
First Named Inventor William E. KLUNK
Group Art Unit 1045 1616
Examiner Name Unassigned
Attorney Docket Number 076333-0281

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		3,257,204		SUS et al.	06/21/1966	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A2	WO	97/26919		Warner Lambert Company	07/31/1997		
	A3	WO	95/06469		Cancer Research Campaign Technology Limited	03/09/1995		
	A4	WO	98/17267		Zymogenetics, Inc., Osteoscreen, Inc. and Univ. of Texas Austin	04/30/1998		
	A5	EP	0 081 141		BASF Akiengesellschaft	12/05/1981		
	A6	EP	0 118 086		Hoechst Aktiengesellschaft	03/02/1983		
	A7	EP	0 287 909		Salutar, Inc.	10/26/1988		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
--------------------	-----------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------

Examiner Signature

[Signature]

Date Considered

11/1/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: April 24, 2002

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number 09/935,767
Filing Date 08/24/2001
First Named Inventor William E. KLUNK
Group Art Unit 1645 / 16 / 16
Examiner Name Unassigned
Attorney Docket Number 076333-0281

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
OIA APR 25 2002 PATENT & TRADEMARK OFFICE	A8	SHI <i>et al.</i> , "Antitumor Benzothiazoles, 3. ¹ Synthesis of 2-(4-Aminophenyl)benzothiazoles and Evaluation of Their Activities against Breast Cancer Cell Lines <i>in Vitro</i> and <i>in Vivo</i> ", <i>J. Med. Chem.</i> , 1996, pp. 3375-3384, Vol. 39, The American Chemical Society.	
	A9	CUADRO <i>et al.</i> , "Styryl and Azastyryl 1,3-Benzazoles with Antihelmitic Activity", <i>Il Farmaco</i> , 1992, pp. 477-488, Vol. 47, No. 4.	
	A10	FOKKEN <i>et al.</i> , "Beitrag zur Darstellung von Verbindungen mit Amidino- bzw. Amidoximstruktur", <i>Pharmazie</i> , 1977, pp. 566-569, <i>Pharmazie</i> 32, H.10 (19).	
	A11	GROZINGER <i>et al.</i> , "Heterocyclic ethenyloxanilates as orally active antiallergic agents, <i>Eur. J. Med. Chem. Chim. Ther.</i> , 1985, pp. 487-491, Vol. 20, No. 6.	
	A12	DRYANSKA, "α-Hydroxybenzylation and Benzylation of the Methyl Group in 2-Methyl-1,3-benzoxazole and 2-Methyl-1,3-benzothiazole" Communications, 1976, pp. 37-38.	
	A13	VAZ <i>et al.</i> , "6-Substituted 2-(p-aminostyryl)benzothiazole derivatives", <i>Indian J. Chem.</i> , 1976, Sect. B, pp. 709-11, Vol. 14B, No. 9.	
	A14	BOGERT <i>et al.</i> , "Researches on Thiazoles, XVII. An Investigation of the Connection Between Constitution and Color in the Thioflavine Group", Collection of Czechoslovak Chemical Communications, 1931, pp. 480-498, Vol. 3, The Chemical Laboratories.	
	A15	MARTVOŇ <i>et al.</i> , "2-Phenyl-6-Benzothiazolyl Isothiocyanates", <i>Collection Czechoslov, Chem. Commun.</i> 1974, pp. 1356-1365, Vol. 39, No. 5.	
	A16	KLUNK <i>et al.</i> , "Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain", <i>Life Sciences</i> , 2001, pp. 1471-1484, Vol. 69, No. 13, Elsevier Pub..	
	A17	WANG <i>et al.</i> , "Synthesis and evaluation of a radioiodinated benzothiazole derivative as a radioligand for in vivo quantitation of beta-amyloid deposits in aging and Alzheimer's disease", <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, pp. S239-S241, Vol. 44, No. Supp. 1.	
	A18	MATHIS <i>et al.</i> , "Lipophilic 11C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease", <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, pp. S26-S28, Vol. 44, No. Supp. 1.	

Examiner Signature

[Handwritten Signature]

Date Considered

11/1/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.